Guardant Health (NASDAQ:GH) Receives “Buy” Rating from Guggenheim

Guggenheim reissued their buy rating on shares of Guardant Health (NASDAQ:GH) in a research report released on Wednesday morning,Benzinga reports.

Several other analysts also recently weighed in on the stock. The Goldman Sachs Group lifted their price objective on shares of Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Leerink Partners reduced their price objective on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Sanford C. Bernstein decreased their price objective on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. lifted their target price on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Fifteen investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $40.60.

Guardant Health Trading Up 4.6 %

NASDAQ:GH opened at $47.20 on Wednesday. The stock has a 50 day moving average of $34.53 and a 200-day moving average of $29.26. The firm has a market capitalization of $5.83 billion, a PE ratio of -11.13 and a beta of 1.28. Guardant Health has a 52 week low of $15.81 and a 52 week high of $49.86.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The company had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. Guardant Health’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.73) earnings per share. As a group, analysts predict that Guardant Health will post -3.44 EPS for the current fiscal year.

Insider Buying and Selling

In other Guardant Health news, Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now directly owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares in the company, valued at approximately $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,548 shares of company stock worth $179,782. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Guardant Health

A number of hedge funds have recently modified their holdings of GH. JNBA Financial Advisors acquired a new stake in shares of Guardant Health during the third quarter worth approximately $26,000. Ashton Thomas Securities LLC purchased a new stake in Guardant Health in the 3rd quarter worth approximately $34,000. Quarry LP acquired a new stake in shares of Guardant Health during the 2nd quarter valued at $44,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Guardant Health during the 2nd quarter valued at $71,000. Finally, Nisa Investment Advisors LLC grew its holdings in shares of Guardant Health by 168.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock valued at $79,000 after acquiring an additional 2,153 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.